V Tiedje


Country: Germany


  1. Tiedje V, Schmid K, Weber F, Bockisch A, Führer D. [Differentiated thyroid cancer]. Internist (Berl). 2015;56:153-66; quiz 167-8 pubmed publisher
    ..Due to its complexity, management of thyroid cancer patients should be performed in close collaboration with a specialized thyroid cancer team. ..
  2. Tiedje V, Ting S, Dralle H, Schmid K, Führer D. [Medullary thyroid carcinoma]. Internist (Berl). 2015;56:1019-31 pubmed publisher
    ..Treatment decisions in incurable MTC must be carefully balanced with treatment-related morbidity, since MTC may take an indolent course over years. ..
  3. Tiedje V, Ting S, Walter R, Herold T, Worm K, Badziong J, et al. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients. Eur J Endocrinol. 2016;175:173-80 pubmed publisher
    ..In this study, we identified molecular markers in primary tumour tissue of sporadic MTC associated with the development of metastasis (both lymph node and organ metastasis) as well as response to vandetanib therapy. ..
  4. Tiedje V, Stuschke M, Weber F, Dralle H, Moss L, Fuhrer D. Anaplastic thyroid carcinoma: review of treatment protocols. Endocr Relat Cancer. 2018;25:R153-R161 pubmed publisher
    ..These protocols then need to be evaluated prospectively to improve ATC patients' outcome in routine care. ..